RSCM
MLTX icon

Rock Springs Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Rock Springs Capital Management’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.15M Hold
61,700
– – 0.07% 93
2025
Q4 		$813K Buy
61,700
+33,500
+119% +$395K 0.04% 96
2025
Q3 		$202K Buy
+28,200
New +$1.47M 0.01% 91
2021
Q4 		– Sell
-154,500
Closed -$1.54M – 144
2021
Q3 		$1.54M Hold
154,500
– – 0.03% 146
2021
Q2 		$1.6M Hold
154,500
– – 0.03% 149
2021
Q1 		$1.58M Hold
154,500
– – 0.03% 145
2020
Q4 		$1.76M Buy
+154,500
New +$1.64M 0.04% 149

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $4.85B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.98B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.43B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $1.94B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $57.5B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return